Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Positive Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Not applicableStudy completedNCT05984615
What this trial is testing

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

Who this might be right for
BRAF Positive Metastatic Melanoma
Novartis Pharmaceuticals 1,961
Not applicableStudy completedNCT06337617
What this trial is testing

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Who this might be right for
BRAF V600 Mutation Positive Melanoma
Novartis Pharmaceuticals 90
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Early research (Phase 1)Study completedNCT01271803
What this trial is testing

Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 131
Not applicableStudy completedNCT06251934
What this trial is testing

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

Who this might be right for
BRAF-positive Metastatic Melanoma
Novartis Pharmaceuticals 785
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096
What this trial is testing

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Who this might be right for
Malignant MelanomaBRAF V600 MutationBrain Metastases
UNICANCER 10
Not applicableStudy completedNCT02310451
What this trial is testing

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Nice 15
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Not applicableStudy completedNCT05260684
What this trial is testing

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Who this might be right for
Melanoma
Pfizer 716
Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Not applicableEnded earlyNCT02700763
What this trial is testing

[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis

Who this might be right for
Melanoma
University Medical Center Groningen 1
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Early research (Phase 1)Ended earlyNCT01400451
What this trial is testing

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Who this might be right for
Melanoma
Bristol-Myers Squibb 18
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Early research (Phase 1)Study completedNCT01107418
What this trial is testing

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 52